HeartSciences (HSCS) Expected to Post Earnings on Thursday

HeartSciences (NASDAQ:HSCS) is anticipated to announce its Q4 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to post earnings of ($0.66) per share and revenue of $0.05 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Friday, July 24, 2026 at 4:00 PM ET.

HeartSciences Stock Down 2.3%

NASDAQ:HSCS opened at $2.56 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.04 and a current ratio of 1.19. The company has a market cap of $8.14 million, a PE ratio of -0.52 and a beta of 1.78. HeartSciences has a 52-week low of $1.63 and a 52-week high of $4.30. The stock has a 50-day simple moving average of $2.18 and a 200 day simple moving average of $2.52.

Wall Street Analysts Forecast Growth

Several research firms have commented on HSCS. Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a research note on Wednesday, June 24th. Ascendiant Capital Markets decreased their price target on shares of HeartSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, HeartSciences presently has an average rating of “Hold” and a consensus price target of $8.00.

Hedge Funds Weigh In On HeartSciences

A hedge fund recently bought a new position in HeartSciences stock. Geode Capital Management LLC acquired a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned approximately 0.51% of HeartSciences at the end of the most recent reporting period. 17.24% of the stock is currently owned by institutional investors.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.